Not Yet RecruitingNot Applicable

HVNI vs NIPPV in Type 2 Respiratory Failure

84 participantsStarted 2025-11-01

Plain-language summary

The purpose of this study is to determine if high velocity nasal insufflation (HVNI) is comparable to non-invasive positive pressure ventilation (NIPPV) in treatment of emergency patients with acute respiratory acidosis. In our non-inferiority trial, we hypothesize that HVNI is inferior to NIPPV in reducing PaCO2 in type 2 respiratory failure (T2RF) due to any cause by a pre-specified non-inferiority margin of 4.3% decrease in PaCO2 levels after 30 minutes of treatment. The primary aim is to evaluate if HVNI is non-inferior to NIPPV in reducing PaCO2 levels in patients with T2RF from any cause. Eligible patients will be randomized to HVNI (intervention) or NIPPV (control).

Who can participate

Age range21 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adult patients aged 21 years and above, who require NIPPV for T2RF due to any cause in the Emergency Medicine Department of the National University Hospital Exclusion Criteria: * patients with "do-not-resuscitate" orders that include NO non-invasive ventilation use \[patients with max NIV status will still be included\] * clinical suspicion or confirmed diagnosis of base of skull fractures or severe facial trauma that precludes NIPPV or nasal cannula placement * vulnerable patient populations (e.g., pregnant women, prisoners) * patients who refused consent * hemodynamic instability (e.g., hypotension requiring immediate resuscitation), cardiac or respiratory arrest * patients who require emergency intubation

What they're measuring

Change in PaCO2 levels at 30 and 60 minutes

Timeframe: 30 minutes and 60 minutes

Trial details

NCT IDNCT07065656

SponsorNational University Hospital, Singapore

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06-30